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The Trimodality
Treatment Approach
in Stage III/pN2
Non–Small Cell Lung
Cancer
“Usually Appropriate”
May Well be a Very
Inappropriate
Treatment Option
To the Editor:
In a recent article, Willers et al1
presented the American College of
Radiology (ACR) appropriateness cri-
teria for the induction and adjuvant
therapy of patients with N2 disease of
stage III non–small cell lung cancer. Our
attention was drawn to a subset of
patients in whom the authors have dis-
cussed the use of induction radio-
chemotherapy (RT-CHT) followed by
surgery. On the basis of an unplanned
subgroup analysis of a single study, the
authors cite2 that trimodality therapy is
“usually appropriate” treatment option.
Whereas the study in concern was neg-
ative by all statistical and scientific
measures (which do not take into account
a post hoc unplanned analysis or any
other surrogates of efficacy), other fully
published studies3,4 also did not show the
superiority of trimodality over exclusive
concurrent RT-CHT. In addition to that,
no high-level evidence exists identifying
the extent of surgery (lobectomy vs.
pneumonectomy) as an important pre-
dictor or even a prognosticator in this
setting. Finally, although we completely
agree that an experienced thoracic sur-
geon is always good to have at hand,
what about an experienced radiation
oncologist? It should be the same way,
isn’t it? Not to mention the seemingly
outdated and, therefore, inferior RT
treatment planning and execution aspects
present during INT0139,2 at least with
respect to the current standards, because
newer RT technologies can definitely
provide a better dose conformity and,
hence, more effective RT.
We firmly believe that evidence-
based oncology principles should be
respected, enabling practicing thoracic
oncologists to offer their patients the best
available treatment option based on the
strongest evidence existing. If so, then it
would be fair to say that there is not a
single piece of strong evidence support-
ing the use of trimodality therapy in this
setting.5 Although we do not exclude the
possibility that there may be a subset of
patients benefitting from it, it is currently
unknown as to which patients we are
speaking about as there is a tremendous
lack of data supporting it. As a matter of
fact, there are no studies attempting
to identify potential predictors of the
superiority of trimodality therapy, and
furthermore, there is also a huge incon-
sistency in the findings of the poor lit-
erature addressing the issue of potential
pretreatment prognostic factors in this
setting. Taken altogether, what may seem
to one as “Usually Appropriate” may
very well be a “Very Inappropriate”
option because we do not know before
the treatment starts (ie, concurrent RT-
CHT regardless of whether followed by
surgery or not) as to which patients
actually may (or may not) benefit the
from trimodality approach. We ulti-
mately believe that nobody wants to
learn that on an operating table or later
on, but rather before any treatment
approach is advocated as the best avail-
able for a particular patient.
An obvious solution to the problem
and the simplest one is the design and the
performance of one or, preferably and
synchronously, more clinical trials in this
setting. That way, we may be able not
only to learn as to which patient sub-
group may potentially benefit from the
trimodality approach but also to perform
adequate predictive factor analyses and
identify subgroups of patients that may
benefit from the trimodality approach
before a patient is even considered for
surgery. We would then be able to save
patients from harm by not offering a
poorly justified treatment approach that is
of similar activity, at best, yet which may
bring up to 10% of mortality in non-
pneumonectomy patients, increasing to
25% in pneumonectomy patients.2–4
Securing full access to and taking into
account all existing evidence is what
makes evidence-based principles supe-
rior to expert-based opinions, no matter
how good in nature the latter is.
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